Clinical Trial

Agnostic Therapy in Rare Solid Tumors

Study acronym: ANTARES
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated April 15, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
The ANTARES study is a phase II basket trial designed to evaluate the tissue-agnostic efficacy of the monoclonal anti-PD1 antibody, nivolumab, in patients with advanced or metastatic rare tumors. The study aims to treat rare malignancies with PD-L1 expression (CPS ≥ 10), regardless of the tumor's tissue type or location. Patients who have not responded to standard treatments will be included, and treatment will last for up to 12 months. The study will assess objective response, progression-free survival, and biomarkers such as PD-L1, ctDNA, and microvesicles, in a multicenter collaborative effort to provide innovative therapeutic options for this underrepresented population
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-10; most recent amendment 2026-04-10.
Status change: Active, Not Recruiting → Recruiting 2026-04-10
Status change: Recruiting → Active, Not Recruiting 2025-05-26
Trial Details
NCT Number NCT06638931
Lead Sponsor Instituto do Cancer do Estado de São Paulo
Collaborators: Financiadora de Estudos e Projetos
Conditions Urachal Cancer, Parathyroid Carcinoma, Fibrolamellar Carcinoma, Angiosarcoma, Secretory Carcinoma of Breast, Anal Neoplasms, Metaplastic Breast Carcinoma, Translocation Renal Cell Carcinoma +33 more
Enrollment 28 participants
Start Date 2024-07-16
Primary Completion 2026-07 (estimated)
Study Completion 2028-05 (estimated)
Updated on ClinicalTrials.gov 2026-04-15